Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.44 |
| ▸ | GCGR | P47871 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | FRK | P42685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31410714 | 0.86 | MEN1 (0.53) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6477468 | 0.83 | PRMT5 (0.59) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29543373 | 0.78 | KDM4E (0.47) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5304507 | 0.77 | MAPT (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL5312078 | 0.77 | MAPT (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL28223244 | 0.73 | AURKA (0.68) | KDM4ENPC1RAB9ASMN1; SMN2MGAM | |
| SCHEMBL8472844 | 0.72 | MEN1 (0.63) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8203276 | 0.72 | MAPK13 (0.56) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6528453 | 0.71 | PRMT5 (0.76) | PRMT5 | |
| Hydrochloric Acid SCHEMBL3201968 | 0.71 | MEN1 (0.61) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | claimed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | claimed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | claimed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | claimed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | claimed |
| US-6891039-B2 | Imidazo [4,5-B] pyridine compounds and their pharmaceuticals use | NOVARTIS AG (CH) | 2005-05-10 | — | — | US | disclosed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | REVESZ LASZLO (CH) | 2004-04-29 | — | — | US | disclosed |
| US-6608072-B1 | Inhibiting production of soluble tumor necrosis factor or reducing inflammation | NOVARTIS AG (CH) | 2003-08-19 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1224185-A1 | THIAZOLE AND IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Novartis AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001030778-A1 | THIAZOLE AND IMIDAZO [4,5-B] PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | MAPK1, IRAK1, IRAK4 | KDM4E 2111/4885NPC1 2584/4885RAB9A 1098/4885 |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | KDM4E 1796/4885NPC1 3808/4885RAB9A 2314/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | KDM4E 1796/4885NPC1 3808/4885RAB9A 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.